Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2020

May 2020 | 487 pages | ID: M9C80BB346CEN
Global Markets Direct

Abstracts

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline Review, H1 2020.doc, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline landscape.

MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections. Risk factors are hemodialysis, weakened immune system, admission to hospitals and wounds. Symptoms include skin rashes, fatigue, chest pain, fever and swelling. MRSA can be managed by the use of antibiotics and by maintaining hygienic conditions.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline Review, H1 2020.doc, provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 14, 8, 2, 79, 31 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 32 and 26 molecules, respectively.

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Overview
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics Development
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics Assessment
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Companies Involved in Therapeutics Development
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drug Profiles
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Discontinued Products
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Products under Development by Companies, H1 2020 (Contd..7), H1 2020
Products under Development by Universities/Institutes, H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by 21st Century Therapeutics Inc, H1 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Absynth Biologics Ltd, H1 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Acticule Life Sciences Ltd, H1 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AEON Medix Inc, H1 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AimMax Therapeutics Inc, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

21st Century Therapeutics Inc
Absynth Biologics Ltd
Acticule Life Sciences Ltd
AEON Medix Inc
AimMax Therapeutics Inc
Allergan Plc
AlphaMab Co Ltd
Amicrobe Inc
Amprologix Ltd
AnyGen Co Ltd
Aphios Corp
Aridis Pharmaceuticals Inc
Arietis Corp
Armata Pharmaceuticals Inc
Atriva Therapeutics GmbH
Aurigene Discovery Technologies Ltd
Basilea Pharmaceutica Ltd
Bharat Biotech Ltd
Biomendics LLC
BioPlx Microbiomics Pvt Ltd
Bioseka UAB
Bioversys AG
Botanix Pharmaceuticals Ltd
Cadila Pharmaceuticals Ltd
Cantab Anti-infectives Ltd
Cellics Therapeutics Inc
Citius Pharmaceuticals Inc
Combioxin SA
Crestone Inc
CrystalGenomics Inc
CSA Biotechnologies LLC
Curza Global LLC
Daiichi Sankyo Co Ltd
Debiopharm International SA
DeNovaMed Inc
Destiny Pharma Plc
Emerald Bioscience Inc
ESA Patentverwertungsagentur Sachsen-Anhalt GmbH
Exbaq LLC
Galenus Therapeutics Inc
GangaGen Inc
Global BioLife Inc Ltd
Helix BioMedix Inc
Helperby Therapeutics Group Ltd
Hsiri Therapeutics LLC
HSRx Group
HyPharm GmbH
Idorsia Pharmaceutical Ltd
Immupharma Plc
Inimmune Corp
Instituto Biomar SA
Integrated BioTherapeutics Inc
ioGenetics Inc
Johnson & Johnson
KBP BioSciences Co Ltd
Kurobe LLC
Lakewood-Amedex Inc
Lead Discovery Center GmbH
LegoChem Biosciences Inc
Lysimmune BioScience
Lyticon LLC
Madam Therapeutics BV
Matrisys Bioscience Inc
Meiji Seika Pharma Co Ltd
Melinta Therapeutics Inc
Merck & Co Inc
MGB Biopharma Ltd
Microbiotix Inc
MicuRx Pharmaceuticals Inc
Motif Bio Plc
Nabriva Therapeutics Plc
Naicons Srl
Neupharma Srl
Novabiotics Ltd
NovaDigm Therapeutics Inc
Novalex Therapeutics Inc
NovoBiotic Pharmaceuticals LLC
Olymvax Biopharmaceuticals Inc
Opal Biosciences Ltd
Oppilotech Ltd
Oragenics Inc
Oryn Therapeutics
Ovensa Inc
Oxford Drug Design Ltd
Peptineo
Phico Therapeutics Ltd
Procarta Biosystems Ltd
Prommune Inc
Q2 Pharma Ltd
QureTech Bio AB
Recce Pharmaceuticals Ltd
Roivant Sciences Ltd
Sano Chemicals Inc
Savara Inc
Scandion Oncology AS
SciBac Inc
Sealife PHARMA GMBH
Sentinella Pharmaceuticals Inc
Shanghai Space Peptides Pharmaceutical Co Ltd
Sinsa Labs Inc
Soligenix Inc
Sorrento Therapeutics Inc
Synspira LLC
TaeJoon Pharmaceuticals Co Ltd
TAXIS Pharmaceuticals Inc
Telephus Medical LLC
TGV Laboratories Inc
TGV-Inhalonix Inc
Therapeutic Systems Research Laboratories Inc
Theravance Biopharma Inc
Trellis Bioscience Inc
Valevia UK Ltd
Venomyx Inc
Viosera Therapeutics
Vitas Pharma Research Pvt Ltd
VLP Biotech Inc
Wockhardt Ltd
XBiotech Inc
Yungjin Pharm Co Ltd
Zhuhai Trinomab Biotechnology Co Ltd